ReviewThe American journal of pathology2023
The Role of Gut Microbiota in Glaucoma Progression and Other Retinal Diseases.
Review in The American journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Transcending genome-wide association studies to create useful multi-omic views of glaucoma.Progress in retinal and eye research · 2026Review
- Fisetin-loaded Nanoemulsion and Fecal Microbiome Extract Enhance In Vitro Inhibition of Non-Small Cell Lung Cancer Progression.Cell biochemistry and biophysics · 2026Article
- The Gut-Eye Axis and Microbiome in Ophthalmic Diseases: A Narrative Review.Journal of clinical medicine · 2026Review
- The Ocular and Gut Microbiome Axis in Understanding Glaucoma: A Systematic Review.Journal of clinical medicine · 2026Review
- The Role of Nutraceuticals in Age-Related Ocular Diseases.Molecules (Basel, Switzerland) · 2025Review
- The Ocular Surface Microbiome in Homeostasis and Dysbiosis.Microorganisms · 2025Review
- Multi-omics Mendelian Randomization Reveals Immunometabolic Signatures of the Gut Microbiota in Optic Neuritis and the Potential Therapeutic Role of Vitamin B6.Molecular neurobiology · 2025Article
- Gut microbiota-derived indoleacetic acid attenuates neuroinflammation and neurodegeneration in glaucoma through ahr/rage pathway.Journal of neuroinflammation · 2025Article
- Associations Between the Gut Microbiota and Its Related Metabolic Pathways and Uveitis: A Bidirectional Two-Sample Mendelian Randomization Study.Translational vision science & technology · 2025Article
- Cannabinoids as Multitarget Drugs for the Treatment of Autoimmunity in Glaucoma.ACS pharmacology & translational science · 2025Review
- Microbiome-based therapeutics for ocular diseases.Clinical & experimental optometry · 2025Review
- Identifying the Involvement of Gut Microbiota in Retinal Vein Occlusion by Mendelian Randomization and Genetic Correlation Analysis.Translational vision science & technology · 2025Article
- Meeting Challenges in the Diagnosis and Treatment of Glaucoma.Bioengineering (Basel, Switzerland) · 2024Article
- Deep Spectral Library of Mice Retina for Myopia Research: Proteomics Dataset generated by SWATH and DIA-NN.Scientific data · 2024Article
- Review
- Article
- A Narrative Review on the Advance of Probiotics to Metabiotics.Journal of microbiology and biotechnology · 2024Review
- Fecal microbiota transplantation for glaucoma; a potential emerging treatment strategy.Current research in microbial sciences · 2024Review
- Unveiling the gut-eye axis: how microbial metabolites influence ocular health and disease.Frontiers in medicine · 2024Review
- Association of Lipopolysaccharide-Type Endotoxins with Retinal Neurodegeneration: The Alienor Study.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As a rapidly growing field, microbiota research offers novel approaches to promoting ocular health and treating major retinal diseases, such as glaucoma. Gut microbiota changes throughout life; however, certain patterns of population changes have been increasingly associated with specific diseases. It has been well established that a disrupted microbiome contributes to central nervous system diseases, including Alzheimer disease, Parkinson disease, multiple sclerosis, and glioma, suggesting a prominent role of microbiome in neurodegenerative diseases. This review summarizes the progress in identifying significant changes in the microbial composition of patients with glaucoma by compiling studies on the association between microbiota and disease progression. Of interest is the relationship between increased Firmicutes/Bacteroidetes ratio in patients with primary open-angle glaucoma, increased taurocholic acid, decreased glutathione, and a reduction in retinal ganglion cell survival. Connecting these microbes to specific metabolites sheds light on the pathogenic mechanism and novel treatment strategies. In summary, the current review synthesizes the findings of several studies investigating the effects of shifting bacterial population in retinal diseases, particularly glaucoma, with the aim to identify the current direction of treatment and help direct future endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.